German Start-Up Remi Health raises €5m to scale Diagnostics-as-a-Service platform across Europe
Berlin,11 March 2026 - Remi Health, the Diagnostics-as-a-Service platform, today announced it has secured an oversubscribed €3 million seed round, bringing total funding to €5 million. The round was led by IBB Ventures, with participation from Catalpa Ventures, MSD Global Health Innovation Fund and existing pre-seed business angels.
Diagnostics across Europe remain fragmented – requiring companies to coordinate collection, logistics, lab operations, medical oversight, and country-specific compliance. Remi Health has built the digital infrastructure layer that enables payers, digital health companies, pharma, and longevity programs to seamlessly embed compliant, scalable diagnostic testing into patient journeys, without rebuilding operations each time.
Since launch, Remi Health has processed over 1 million diagnostic tests and is currently supporting programs with several major healthcare payers and partners across Europe, working alongside laboratory partners to expand a cross-border network designed for scalable, multi-market diagnostics.
“Decentralised care only works if diagnostics are accessible, trusted, and seamlessly embedded,” said Anthony Bielenstein, Co-CEO of Remi Health. “We remove complexity, so our partners can focus on product innovation, care models, and post-result patient journeys.”
“Labs are the backbone of diagnostics, but most weren’t built for digital-first care,” said Marvin Abert, Co-CEO of Remi Health. “Our platform integrates with lab partners to scale efficiently, utilise unused capacity, and enable access to new sample streams by participating in distributed health journeys without adding operational complexity.”
The new capital will be used to expand Remi Health’s cross-border laboratory network and broaden European coverage, while scaling decentralised collection methods – including at-home, on-site, and partner collection models - to support multi-country diagnostics programs. The company will also advance regulatory coverage across new markets and deepen enterprise partnerships with payers, pharma, and health solution providers.
Remi Health is preparing the launch of its open diagnostics network, expanding beyond core infrastructure with the goal to process 100 million diagnostic tests by 2030, establishing Remi Health as the digital layer for decentralised diagnostics across Europe.
“As diagnostics move beyond the clinic and become more decentralised, competitive advantage shifts to the underlying infrastructure,” said Prof. Silke Sperling, Managing Partner & Founder of Catalpa Ventures. “Remi Health provides the foundational systems that enable this ecosystem to scale.”
“Berlin has become one of Europe’s leading hubs for health innovation, and Remi Health is a strong example of the infrastructure companies emerging from this ecosystem,” said Ulrike Kalapis, Senior Investment Manager at IBB Ventures. “Their platform connects laboratories with the growing demand for decentralised diagnostics - building the kind of scalable, cross-border infrastructure that the market needs.”
About Remi Health
Remi Health is a Diagnostics-as-a-Service platform used by payers, digital health companies, longevity companies, pharma companies, and healthcare providers to embed diagnostics into their products through a single integration. Operating across multiple European markets, Remi Health partners with leading laboratories and combines decentralised collection, lab connectivity, regulatory compliance, medical oversight, and digital patient experiences into one scalable solution.
About Catalpa Ventures
Catalpa Ventures is the first Luxembourg-based venture capital fund specializing in early-stage investments in European HealthTech startups. The firm was founded in 2024 by an interdisciplinary team of physicians, venture capital experts, and entrepreneurs. Its mission is to improve the health of 100 million people by supporting solutions that address three key challenges facing today’s healthcare systems: aging populations, workforce shortages, and rising costs.
About MSD Global Health Innovation Fund
MSD Global Health Innovation Fund (MGHIF) is a growth investor partnering with innovative digital health and data science companies that facilitate and optimize biopharmaceutical operations with the goal of improving patient care. This investment strategy connects innovative companies with complementary technologies to develop integrated health care solutions. MGHIF has $600M under management and provides growth capital to emerging health care technology companies worldwide while leveraging the vast R&D-based, global resources of MSD. With a vision that data will be the currency in health care, MGHIF invests broadly in digital health. MGHIF invests in platform companies with proven technologies or business models where MSD’s expertise and perspectives can accelerate revenue growth and enhance value creation.
About IBB Ventures
IBB Ventures has been providing venture capital to innovative Berlin-based companies since 1997 and is one of the most activeearly-stage investors in Berlin. In addition to its two VC funds for technology and creative industries with a combined volume of€100 million, and the €30 million Impact VC Fund launched in 2022, the €10 million Pre-Seed Fund B# (“be sharp”) for Berlin-based deep-tech startups has been in its investment phase since 2025. The funds are financed through the European Regional Development Fund (ERDF) and Investitionsbank Berlin (IBB).
To date, IBB Ventures has invested in approximately 300 Berlin-based companies. Together with investment partners in consortia,these startups have raised more than €2 billion in total, of which IBB Ventures has contributed more than €300 million as lead,co-lead, or co-investor. IBB Ventures is the umbrella brand for the VC activities of IBB Beteiligungsgesellschaft and part of theIBB Group.
Kontakt:
Ulrike Kalapis
IBB Ventures
Bundesallee 210
10719 Berlin
Tel: +49 (0)30 2125 3201
Mail: info@ibbventures.de